TAM May 2025 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
May 2025, Volume 33, Issue 2
Overview
- CME Credit Available: 9.0 AMA PRA Category 1 Credits™
- Release Date: May 21, 2025
- Expiration Date: May 21, 2026
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 5 articles, the learner will be better able to:
- List the changes made to the 2025 edition of the International Antiviral Society–USA (IAS–USA) drug resistance mutations Figure, and describe how the Figure assists practitioners in identifying key mutations associated with resistance to antiretroviral drugs
- Describe the latest information on liver disease in people with HIV identified at the Ninth Biennial HIV and Liver Disease Conference
- Describe the important new data presented at the 2025 Conference on Retroviruses and Opportunistic Infections on neuropsychiatric complications in people with HIV; clinical presentation, diagnosis, and treatment options for tuberculosis, mpox, and other opportunistic infections in adults and children with HIV; and epidemiologic trends and the latest preventative methods for HIV and other sexually transmitted infections
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from May 21, 2025, to May 21, 2026. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Contributors
Dr Buchbinder reported institutional grants/grants pending to her institution from Gilead Sciences, Inc., GlaxoSmithKline, Merck, and ViiV Healthcare; and noncash provision of medicines, equipment, or administrative support from Gilead Sciences, Inc. (Updated April 9, 2025)
Dr Calvez reported serving as a board member, advisor, or consultant to, and receiving research grants to his institution from Moderna, Merck Sharp & Dohme, Inc, ViiV Healthcare, and Gilead Sciences, Inc. (Updated March 5, 2025)
Dr Ceccherini-Silberstein reported consulting for ViiV Healthcare,Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc, and receiving research grants from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc. (Updated March 21, 2025)
Dr Chan reported no financial relationships with ineligible companies. (Updated May 8, 2025)
Dr Charpentier reported serving as an advisor to ViiV Healthcare, Gilead Sciences, Inc, Janssen Therapeutics, Theratechnologies, and Merck Sharp & Dohme, Inc, and receiving research grants from ViiV Healthcare. (Updated March 21, 2025)
Dr Corley reported no financial relationships with ineligible companies. (May 8, 2025)
Dr Günthard reported serving as a consultant to Merck & Co, Inc, ViiV Healthcare, GlaxoSmithKline, Novartis, Johnson andJohnson, Inc, and Gilead Sciences, Inc’ and
receiving research grants from Gilead Sciences, Inc. (Updated November 7, 2024)
Dr Havlir reported nonfinancial support from ViiV Healthcare. (Updated April 11, 2025)
Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated May 20, 2025)
Dr Joseph reported no financial relationships with ineligible companies. (Updated May 8, 2025)
Dr Kerkhoff reported no financial relationships with ineligible companies. (Updated April 11, 2025)
Dr Liu reported institutional grants/grants pending to her institution from Gilead Sciences, Inc., GlaxoSmithKline, Merck, and ViiV Healthcare; and noncash provision of medicines, equipment, or administrative support from Gilead Sciences, Inc. (Updated April 9, 2025)
Dr Paredes reported receiving research grants from ViiV Healthcare and Merck Sharp & Dohme, Inc, and serving as a consultant to Gilead Sciences, Inc, ViiV Healthcare, Pfizer, Inc, Theratechnologies, Inc, and Eli Lilly and Company. (Updated March 21, 2025)
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated March 10, 2025)
Dr Shafer reported receiving research grants from Janssen Therapeutics, Vela Diagnostics, and InSilixa, Inc; and receiving personal consulting fees from Abbott Diagnostics. (Updated March 21, 2025)
Dr Sherman reported receiving grant support or contracts awarded to his institution from AbbVie, Gilead Sciences, Inc, Intercept Pharmaceuticals, Inc,
Zydus, and Helio; and serving on data and safety monitoring boards for Medpace Inc., Pliant, and Horizon/AMGEN. (Updated February 4, 2025)
Dr Thomas reported consulting or advising fees from Excision Bio; and fees for participation in review activities from Merck. (Updated February 4, 2025)
Dr Tien reported receiving grant support awarded to her institution from Merck.
(Updated February 4, 2025)
Dr Wensing reported serving on advisory boards for ViiV Healthcare, Glaxo-Smith Kline, Janssen Therapeutics, and Gilead Sciences, Inc, and receiving investigator-initiated research grants from Gilead Sciences, Inc. (Updated March 21, 2025)
Dr Zucker reported no financial relationships with ineligible companies. (Updated
April 11, 2025)
Planners/Reviewers
Reviewer 1 reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated March 10, 2025)
Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated April 30, 2025)
Reviewer 3 reported no relevant financial relationships with ineligible companies. (Updated May 20, 2025)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated March 10, 2025)
Dr Benson reported receiving research grants from DNAe Group Holdings, Ltd, BioMerieux, and Gilead Sciences, Inc; serving as a consultant to NDA Partners LLC; serving as a scientific advisory board member for the INTREPID Alliance and Antiva, Inc., and as a member of a Data Safety Monitoring Board for ViiV/GlaxoSmithKline. (Updated April 30, 2025)
Dr Hirsch reported no relevant financial relationships with ineligible companies. (Updated April 30, 2025)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.